[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-cancer":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,123,0,25,[9,50,76,95,124,155,178,212,242,273,290,329,356,378,400,438,470,493,523,547,581,601,638,695,733],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":4,"leadSponsor":46,"locationsCount":49},"100060621","collection-of-blood-from-patients-with-cancer-100060621",false,"NCT00034216","Collection of Blood From Patients With Cancer","Biospecimen Acquisition From Human Subjects","* INCLUSION CRITERIA:\n\nPatients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible.\n\nPerformance status of ECOG 0, 1, 2, or 3 for admission to this protocol.\n\nAbility to understand and the willingness to sign a written informed consent document.\n\nINCLUSION FOR APHERESIS:\n\nNote: Effective with Amendment CC, participants will no longer be asked to undergo apheresis. This content is being retained for historical reference.\n\nHemoglobin greater than or equal to 10 mg\u002FdL and platelet count \\> 75,000\u002Fmm(3)\n\nWeight greater than 25 kg\n\nHIV negative\n\nProthrombin Time - within normal limits\n\nPartial Thromboplastin Time - within normal limits\n\nMedically indicated central line in place or adequate peripheral venous access\n\nEXCLUSION CRITERIA:\n\nNone.",true,"ALL","18 Years",{"count":21,"type":22},1750,"ESTIMATED","OBSERVATIONAL","This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment.\n\nParticipants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment.",[26,27,28,29,30],"Prostate Cancer","Breast Cancer","Colon Cancer","Lung Cancer","Liver Cancer",[32,33,34,35,36,37,38],"Suppressor Cells","T-cells","CD4+ \u002F CD25+ cells","Natural History","Cancer","Malignancy","Blood Sample","RECRUITING","2026-08-12",{"date":42,"type":43},"2026-08-13","ACTUAL",{"date":45,"type":43},"2002-07-16",{"name":47,"class":48},"National Cancer Institute (NCI)","NIH",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":49},"100651641","phase-1-ymn-136-vaccine-for-patients-with-advanced-hepatobiliary-and-pancreatic-malignancies-100651641","NCT07763301","YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies","YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies: A Prospective, Phase I Clinical Trial","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form, and be able to understand and agree to comply with the study procedures and visits as specified in the protocol.\n2. Age: 18 to 75 years old, male or female.\n3. Patients with pathologically or histologically confirmed, unresectable advanced hepatobiliary and pancreatic malignancies who must have experienced disease progression after receiving standard anti-tumor therapy, or who are unable to receive or tolerate standard therapy, or who refuse standard therapy:\n\n(1) Patients with advanced hepatocellular carcinoma who have failed standard therapy, defined as disease progression after prior treatment with PD-(L)1 and mTKI systemic therapy (either separately or in combination), or discontinuation of treatment due to intolerance to toxicity; (2) Patients with advanced biliary tract cancer who have failed standard therapy, defined as disease progression after prior treatment with gemcitabine-containing systemic therapy and non-cytotoxic therapy (i.e., targeted therapy or immunotherapy), or discontinuation of treatment due to intolerance to toxicity; (3) Patients with advanced pancreatic cancer who have failed standard therapy, defined as disease progression after prior treatment with at least two systemic therapies (must include fluoropyrimidines and gemcitabine), or discontinuation of treatment due to intolerance to toxicity.\n\n4\\. Positive IMP3 expression. 5. At least one evaluable lesion according to RECIST v1.1. 6. Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1. 7. Life expectancy ≥ 12 weeks. 8. Organ function levels at screening must meet the following requirements:\n\n1. Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL;\n2. Platelet count (PLT) ≥ 75 × 10⁹\u002FL;\n3. Hemoglobin (Hb) ≥ 90 g\u002FL;\n4. Total bilirubin (TBIL) ≤ 1.5 × ULN;\n5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, or ≤ 5 × ULN in patients with liver metastases;\n6. Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance (Cockcroft-Gault formula) ≥ 45 mL\u002Fmin;\n7. International normalized ratio (INR) and prothrombin time (PT) ≤ 1.5 × ULN;\n8. QTc interval calculated by Fridericia's formula ≤ 450 ms for males and ≤ 470 ms for females;\n9. Urinalysis\u002F24-hour urine protein quantification: urine protein qualitative ≤ 1+ (if urine protein qualitative ≥ 2+, 24-hour urine protein \\\u003C 1 g is acceptable for enrollment);\n10. Cardiac function: left ventricular ejection fraction ≥ 50%. 9. Eligible patients (male or female) with childbearing potential must agree to use a medically accepted physical contraceptive method (e.g., intrauterine device, condom, tubal or vas deferens ligation, etc.) during the study period and for 6 months after the last dose. Female patients of childbearing potential must have a negative serum or urine HCG test at screening.\n\nExclusion Criteria:\n\n1. Presence of extensive peritoneal metastasis or intestinal obstruction.\n2. Presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.\n3. Known allergy to any component of the investigational drug (e.g., lipid nanoparticles, RNA carrier) or to drugs of the same class.\n4. Prior receipt of vaccine therapy.\n5. Received chemotherapy, targeted therapy, or immunotherapy within 4 weeks prior to the first dose.\n6. In the dose-escalation and dose-expansion phases: received anti-tumor therapy (including chemotherapy, radiotherapy, targeted therapy, immunotherapy, biological therapy, or other investigational drug therapy for target lesions) within 4 weeks or 5 drug half-lives (whichever is shorter, but at least 14 days) prior to the first dose; or received traditional Chinese medicine or Chinese patent medicine with anti-tumor indications within 14 days prior to the first dose.\n7. Use of immunosuppressive drugs within 4 weeks prior to the first dose or expected use during the study period, except for corticosteroid nasal sprays, inhalers, or systemic prednisone ≤ 10 mg\u002Fday (or equivalent doses of similar drugs).\n8. History of organ transplantation, bone marrow transplantation, or hematopoietic stem cell transplantation.\n9. Receipt of a live attenuated vaccine within 28 days prior to the first dose.\n10. In the dose-escalation and dose-expansion phases: presence of symptomatic, untreated, or central nervous system (CNS) metastases requiring ongoing treatment (including corticosteroids and antiepileptics). Patients with previously treated CNS metastases may be enrolled if they have been clinically stable for at least 4 weeks prior to enrollment, have no evidence of new or enlarging metastases, and have discontinued corticosteroid therapy. Patients with asymptomatic CNS metastases not requiring treatment may be enrolled.\n11. In the dose-escalation and dose-expansion phases: toxicity from prior anti-tumor therapy that has not recovered to baseline or to Grade 0-1 per NCI-CTCAE v5.0 (except for alopecia and hyperpigmentation). Irreversible toxicities that are reasonably not expected to be exacerbated by the study drug may be enrolled after confirmation with the investigator.\n12. History of autoimmune diseases, such as systemic lupus erythematosus, psoriasis requiring systemic therapy, rheumatoid arthritis, inflammatory bowel disease, etc. Patients with type I diabetes mellitus, hypothyroidism controlled with replacement therapy only, or skin diseases not requiring systemic therapy (e.g., vitiligo, psoriasis) may be enrolled.\n13. History of immediate hypersensitivity reactions, eczema, or asthma that cannot be controlled with topical corticosteroids.\n14. History of other malignancies, except for curatively treated curable tumors, such as basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or carcinoma in situ of the breast.\n15. Presence of uncontrolled comorbid conditions, including but not limited to: unexplained fever \\> 38.5°C (patients with tumor-related fever to be enrolled at the investigator's discretion); symptomatic congestive heart failure of New York Heart Association (NYHA) class ≥ 2; left ventricular ejection fraction (LVEF) \\\u003C 50%; poorly controlled hypertension (systolic blood pressure \\> 160 mmHg and\u002For diastolic blood pressure \\> 100 mmHg after treatment, and assessed as clinically significant by the investigator); unstable angina or acute myocardial infarction within 3 months prior to the first dose; poorly controlled arrhythmia; chronic obstructive pulmonary disease, asthma, or interstitial lung disease with impaired pulmonary function.\n16. Presence of active infection currently requiring systemic anti-infective therapy; patients with active tuberculosis.\n17. Known positive for human immunodeficiency virus (HIV) or active syphilis infection; HBsAg and\u002For HBcAb positive with HBV-DNA \\> 500 IU\u002FL; HCV-RNA positive.\n18. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study, including but not limited to any disease or medical history that may confound the study results or interfere with patient compliance.","75 Years",{"count":59,"type":22},9,"INTERVENTIONAL",[62],"PHASE1","This study aims to determine the safety and maximum tolerated dose (MTD) of YMN-136 vaccine through a dose escalation trial, and to investigate whether YMN-136 vaccine can assist in the treatment of patients with advanced hepatobiliary and pancreatic malignancies.",[30,65,66],"Pancreatic Cancer","Biliary Tract Cancer (BTC)","2026-08-10",{"date":42,"type":43},{"date":70,"type":43},"2026-08-01",{"date":72,"type":22},"2028-05-31",{"name":74,"class":75},"West China Hospital","OTHER",{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":60,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100597021","phase-1-pd-1-mrna-lnp-vaccine-for-advanced-primary-hepatocellular-carcinoma-100597021","NCT07053072","PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.","A Prospective，Single Arm Clinicial Trial Evaluating PD-1 mRNA LNP Vaccine for the Treatment of Advanced Primary Hepatocellular Carcinoma Failing Standard Therapy","Inclusion Criteria:\n\n1. Male or female patients: ≥18 years of age; ≤70 years of age;\n2. Recurrent or metastatic hepatocellular carcinoma that has failed second-line standard therapy.\n3. Patients with at least one target lesion with a measurable diameter according to the RECIST criteria (CT scan of tumor lesions with a long diameter of ≥10mm, CT scan of lymph node lesions with a short diameter of ≥10mm and a layer thickness of no more than 5mm);\n4. ECOG physical condition score: 0 to 1;\n5. Expected survival ≥ 3 months;\n6. Good function of major organs, i.e., relevant examination indexes within 14 days prior to randomization meet the following requirements:\n\n   * Routine blood tests: hemoglobin ≥80g\u002FL (no blood transfusion within 14 days); neutrophil count \\>1.5×109 \u002FL; platelet count ≥80×109 \u002FL;\n   * Biochemical tests: total bilirubin ≤1.5 × ULN (upper limit of normal); blood alanine aminotransferase (ALT) or blood alanine transaminase (AST) ≤ 2.5 × ULN; if liver metastases, ALT or AST ≤ 5 × ULN; endogenous creatinine clearance ≥ 60 ml\u002Fmin (Cockcroft-Gault formula);\n   * cardiac Doppler ultrasound: left ventricular ejection fraction (LVEF) (LVEF) ≥50%.\n7. Good compliance and family agreement to cooperate in receiving survival follow-up.\n\nExclusion Criteria:\n\n1. Participation in a clinical trial of another drug within 4 weeks;\n2. Patients with a prior history of other neoplasms, unless cervical cancer in situ, treated squamous skin cancer or epithelial tumor of the bladder or other malignancies that have undergone radical therapy (at least 5 years prior to enrollment);\n3. Patients with uncontrolled cardiac clinical symptoms or disease, such as NYHA class 2 or higher heart failure, unstable angina pectoris , myocardial infarction within 1 year, clinically significant Supraventricular or ventricular arrhythmias requiring treatment or intervention.\n4. For female subjects: women who are pregnant or breastfeeding.\n5. Patients with active tuberculosis, bacterial or fungal infection (≥ grade 2 of NCI-CTCAE 5.0); HIV infection; active HBV infection; HCV infection.\n6. Those with a history of psychotropic substance abuse that they are unable to abstain from or those with mental disorders;\n7. Subjects with any active autoimmune disease or history of autoimmune disease (e.g., the following, but not limited to : uveitis, enteritis, pituitary gland inflammation, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or asthma that has resolved completely in childhood and does not require any intervention in adulthood may be enrolled; subjects with asthma requiring medical intervention with bronchodilators may not be enrolled).\n8. Patients who have been inoculated with mRNA drugs.\n9. Participation in clinical trials involving lipid nanoparticles, a component of the study vaccine.\n10. Contraindications to intramuscular injection.\n11. History of substance abuse or known medical, psychological or social conditions such as alcohol or drug abuse.\n12. Known allergy, hypersensitivity or intolerance to the investigational vaccine (including any excipients). Previous history of severe allergy to any drug, food, or vaccination, such as anaphylaxis, allergic laryngeal edema, allergic dyspnea, anaphylactic purpura, thrombocytopenic purpura, localized anaphylactic necrotic reaction (Arthus reaction).\n13. The female subject is planning to become pregnant or the male subject's partner is planning to become pregnant during the Screening Period and up to 12 months after the full course of drug administration.\n14. In the judgment of the investigator, there is a serious concomitant disease that jeopardizes the patient's safety or interferes with the patient's ability to complete the study.","70 Years",{"count":59,"type":22},[62],"Evaluating the Safety and Efficacy of PD-1 mRNA LNP Vaccine Therapy in Patients with Primary Hepatocellular Carcinoma Who Have Failed Advanced Standard Therapy",[30],{"date":42,"type":43},{"date":90,"type":43},"2025-10-23",{"date":92,"type":22},"2026-12-30",{"name":74,"class":75},2,{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":60,"phases":105,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100522562","phase-4-national-liver-cancer-screening-trial-100522562","NCT06084234","National Liver Cancer Screening Trial","TRACER","Inclusion Criteria:\n\nPatient must meet all of the following inclusion criteria:\n\n1. Adult patients ages 18-85 with cirrhosis from any etiology or with chronic hepatitis B with a PAGE-B score greater than 9 within 12 months of enrollment\n2. Patient is eligible for HCC surveillance according to treating physician or by the site investigator\n3. Able to provide informed consent\n4. Life expectancy \\>6 months (after consent) as determined by the treating provider or site investigator\n\nExclusion Criteria:\n\nPatient will be excluded for any of the following exclusion criteria:\n\n1. Child Pugh C cirrhosis\n2. History or clinical symptoms of hepatocellular carcinoma or cholangiocarcinoma\n3. History of solid nodule on baseline ultrasound (i.e., lesion 1cm or greater) within 9 months prior to consent without subsequent diagnostic CT\u002FMRI demonstrating benign nature)\n4. AFP \\>20 ng\u002FmL within 6 months prior to consent, in the absence of a contrast-enhanced CT or MRI within 6 months of AFP (before or after) level demonstrating lack of suspicious liver lesions\n5. Newly diagnosed LR-3 greater than or equal to 1 cm within 6 months prior to consent\n6. History of LR-4, LR-5, or LR-M on multi-phase CT or contrast-enhanced MRI within 6 months prior to consent\n7. Presence of another active cancer besides non-melanomatous skin cancer or indolent cancer under active surveillance (e.g., prostate cancer or renal cell carcinoma) within the 2 years prior to consent\n8. Patient's provider is planning to use MRI- or CT- based surveillance moving forward\n9. History of a transjugular intrahepatic portosystemic shunt (TIPS)\n10. History of Fontan associated liver disease or cardiac cirrhosis\n11. History of solid organ transplantation\n12. Actively listed for liver transplantation\n13. Diagnosis of alcohol-associated hepatitis within 3 months prior to consent\n14. Documented current or continued signs and symptoms of acute Wilson disease (acute liver failure, acute neurological deficits, hemolysis)\n15. In patients with primary sclerosing cholangitis (PSC): Current active cholangitis within 90 days prior to consent\n16. Known or documented habitual non-adherence to previous research studies or medical procedures or unwillingness to adhere to protocol (e.g., unwilling to obtain consent or samples)\n17. In patients living with HIV: CD4+ T cell count less than 100 cells\u002Fmm3 within 60 days prior to consent\n18. Known pregnancy at consent\n19. Active warfarin use","85 Years",{"count":104,"type":22},5500,[106],"PHASE4","The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), and HCC etiology (viral vs. non-viral). Patients will be recruited from 15 sites (mix of tertiary care and large community health systems) over a 3-year period, and the primary endpoint of the phase IV trial, reduction in late-stage HCC, will be assessed after 5.5 years.",[109,30,110,111],"Carcinoma, Hepatocellular","Liver Cirrhosis","Hepatitis B",[113,114,115],"Hepatocellular carcinoma surveillance","GALAD","Alpha Fetoprotein",{"date":40,"type":43},{"date":118,"type":43},"2023-12-26",{"date":120,"type":22},"2034-12-31",{"name":122,"class":75},"University of Texas Southwestern Medical Center",19,{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":60,"phases":134,"briefSummary":136,"conditions":137,"keywords":142,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":49},"100585191","hepquant-study-to-assess-the-role-of-blood-based-biomarkers-and-quantitative-mr-imaging-for-patients-receiving-radiation-therapy-for-liver-cancer-100585191","NCT06899152","HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer","HepQuant: Pilot Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer","HepQuant","The following criteria must be met for subjects to be considered for the trial. Additional exclusion criteria must be met for subjects interested in the HepQuant subset of the trial. The first 20 qualifying subjects will be enrolled for the additional HepQuant test.\n\nInclusion Criteria:\n\n* Age \\> 18\n* Patient has the psychological ability and general health needed to provide informed consent, completion of study requirements, and required follow-up\n* Patient provides study-specific informed consent prior to study entry\n* All primary histologies (Hepatocellular carcinoma or Cholangiocarcinoma) as well as hepatic metastases are eligible\n* Prior history of radiation therapy (external beam or radioembolization) is allowed, with no limit to the number of prior courses of radiation therapy\n* Any number of lesions (with no size limit) of pathologically documented (histologically or cytologically) or radiographically proven tumor\u002Fmetastasis that are being targeted\n* Prior history of liver resection, transarterial chemoembolization (TACE), or ablation are allowed with no restriction on number of prior therapies, or time from current study registration\n* Prior history of chemotherapy, immunotherapy, or targeted biological therapy is allowed\n* Concurrent enrollment on other prospective registry or treatment intention trials is allowed\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding females\n* Subjects with history of claustrophobia impacting ability to perform MRI during the study\n* Subjects who fulfill any of the contraindications for MRI; examples include any ferromagnetic material, any metallic shrapnel or fragments or implanted electronic devices contained within the body or metal-containing tattoos\n* Unable to participate in MR assessments due to physical limitations of equipment tolerances (MRI bore size and\u002For weight limit)\n* Any person unable to lie still within the environment of the MRI scanner or maintain a breath hold for the required period to acquire images\n\nExclusion criteria for HepQuant SHUNT DuO testing ONLY:\n\n* Known history or suspected hypersensitivity to human serum albumin, or its preparations\n* Subjects with extensive resection of large segments of small intestine (short gut) or severe gastroparesis (e.g., diabetic or medication-induced gastroparesis)\n* Subjects on either a non-selective beta blocker (propranolol, nadolol), or an angiotensin converting enzyme (ACE) inhibitor, or angiotensin receptor blocker (ARB) who are unwilling or unable to delay taking their normal dose the morning of their testing\n* Subjects who are allergic to any ingredient in the formulations or components in the HepQuant SHUNT DuO kit including the human serum albumin (HSA) or cholate compounds (theoretical - none yet reported)\n* Subjects unwilling or unable to fast for at least 5 hours. Fasting means no intake of food or food supplements, including fiber preparations or biosimilars; or any preparations or resins (cholestyramine, colestipol, colesevelam) that might act within the gut lumen to bind the orally administered d4-cholate in the HepQuant test.",{"count":133,"type":22},40,[135],"NA","This is a pilot and feasibility study assessing the role of quantitative multiparametric MRI and blood-based biomarkers for the measurement of liver function in patients receiving radiation therapy for liver cancer, including hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver metastases regardless of primary histology, that are undergoing photon radiation either in the de-novo or re-irradiation setting. The goal of this study is to prospectively evaluate the feasibility of using quantitative multiparametric MRI to monitor liver function at baseline and following liver radiation therapy.",[30,138,139,140,141],"Hepatocellular Carcinoma","Hepatocellular Cancer","Cholangiocarcinoma","Liver Metastases",[143,144,145],"Blood-based biomarkers","Quantitative MR imaging","Radiotherapy","2026-08-07",{"date":148,"type":43},"2026-08-11",{"date":150,"type":43},"2025-07-16",{"date":152,"type":22},"2031-07",{"name":154,"class":75},"Montefiore Medical Center",{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":49},"100593736","development-and-testing-of-a-patient-facing-educational-tool-about-liver-cancer-prevention-100593736","NCT07010315","Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention","Inclusion Criteria:\n\n* At least 18 years old\n* Participants at the HOPE Clinic\n* Able to speak and read either English or Spanish\n* For usability testing: Able to use and navigate websites on own smart phone or study computer\n\nExclusion Criteria:\n\n* Has been diagnosed with liver cancer\n* Cannot provide consent or otherwise participate in research activities (e.g. vision or hearing impairment)",{"count":133,"type":22},"To develop and test liver cancer prevention educational material.",[30],[165,166,167,168],"Liver cancer","Liver disease","Fibrosis","Cirrhosis","2026-08-05",{"date":171,"type":43},"2026-08-06",{"date":173,"type":43},"2025-05-01",{"date":175,"type":22},"2027-04-30",{"name":177,"class":75},"M.D. Anderson Cancer Center",{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":60,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100597545","distance-based-exercise-to-preserve-function-and-prevent-disability-100597545","NCT07059884","Distance-Based Exercise to Preserve Function and Prevent Disability","DEFEND","Inclusion Criteria:\n\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed diagnosis of one of the following cancers: anus, bladder, breast, cervix, colon\u002Frectum, endometrium, esophagus, gallbladder, head\u002Fneck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, stomach\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting are eligible. Patients receiving definitive chemoradiation for the tumors listed above, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have metastatic cancer\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of current alcohol, substance abuse, or dementia\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Engaged in full time gainful employment of at least 30 hours per week at the time of cancer diagnosis\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Currently no self-report of engagement in competitive sports (e.g. not training for running races, triathlons, etc.) AND no self-report of twice weekly progressive resistance exercise training for at least 3 consecutive months within the past year\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Self-reported ability to walk for 6 minutes (use of assistive devices will be allowed)\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not participating in another weight loss, physical activity, or dietary intervention clinical trial\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Predicted 6MWT distance of 550 meters or less\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Concurrent enrollment in treatment or supportive care trials (other than those focused on weight loss or exercise) is allowed with the permission of the Alliance Executive Officer and both studies' study chairs\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): The trial is unable to accommodate the needs of deaf or blind participants as the study relies on language and visualization of exercise through telehealth sessions\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Clinicians and research staff from enrolling sites who meet following criterion will be deemed eligible to participate as a clinical stakeholder:\n\n  \\* Providing clinical care for participating patients on this study\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Ability to speak and understand English\n\nExclusion Criteria:\n\n\\-",{"count":186,"type":22},104,[135],"This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.",[190,191,192,27,193,28,194,195,196,197,198,30,29,199,200,65,26,201,202],"Localized Malignant Solid Neoplasm","Anal Cancer","Bladder (Urothelial, Transitional Cell) Cancer","Cervical Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastric Cancer","Kidney Cancer","Head and Neck Cancer","Ovarian Cancer","Rectal Cancer","Sarcoma","2026-08-04",{"date":169,"type":43},{"date":206,"type":43},"2026-02-11",{"date":208,"type":22},"2027-08-31",{"name":210,"class":75},"Alliance for Clinical Trials in Oncology",18,{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":18,"minAge":219,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":60,"phases":223,"briefSummary":224,"conditions":225,"keywords":231,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":235,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":49},"100417400","phase-1-interleukin-15-and--21-armored-glypican-3-specific-chimeric-antigen-receptor-expressed-in-t-cells-for-pediatric-solid-tumors-100417400","NCT04715191","Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors","Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)","Procurement Eligibility\n\nInclusion Criteria:\n\n* Diagnosis of GPC3-positive\\* solid tumors (as determined by immunohistochemistry with an extent score of \\>=Grade 2 \\[\\>25% positive tumor cells\\] and an intensity score of \\>= 2 \\[scale 0-4\\]).\n* Age ≥1 year and ≤ 21 years\n* Lansky or Karnofsky score ≥60%\n* Life expectancy ≥16 weeks\n* Barcelona Clinic Liver Cancer Stage A, B or C (for patients with hepatocellular carcinoma only)\n* Child-Pugh-Turcotte score \\\u003C7 (for patients with hepatocellular carcinoma only)\n* Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent\n\nExclusion Criteria:\n\n* History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies).\n* History of organ transplantation\n* Known HIV positivity\n* Active bacterial, fungal or viral infection (except Hepatitis B or Hepatitis C virus infections)\n\nTreatment Eligibility\n\nInclusion Criteria:\n\n* Age ≥ 1 year and ≤ 21 years\n* Barcelona Clinic Liver Cancer Stage A, B or C (for patients with hepatocellular carcinoma only)\n* Lansky or Karnofsky score ≥ 60%\n* Child-Pugh-Turcotte score \\\u003C 7 (for patients with hepatocellular carcinoma only)\n* Adequate organ function:\n* Creatinine clearance as estimated by Cockcroft Gault or Schwartz ≥ 60 ml\u002Fmin\n* Total bilirubin \\\u003C 3 times ULN for age\n* INR ≤1.7 (for patients with hepatocellular carcinoma only)\n* Absolute neutrophil count \\> 750\u002Fµl\n* Platelet count \\> 75,000\u002Fµl (Needs to be confirmed prior to treatment whether with or without transfusion)\n* Hgb ≥ 8.0 g\u002Fdl (Needs to be confirmed prior to treatment whether with or without transfusion)\n* Pulse oximetry ≥ 92% on room air\n* Incurable disease after treatment with up- front therapy (Patients who have relapsed disease despite a standard of care salvage therapy)\n* Wash out period, such that patient has recovered from acute toxic effects of all prior chemotherapy and investigational agents before entering this study, and returned to their clinical baseline, as determined by history and physical exam.\n* Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the T-cell infusion.\n* Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Uncontrolled infection\n* Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent\u002Fkg\u002Fday, dose adjustment or discontinuation of medication must occur at least 24 hours prior to CAR T cell infusion)\n* Known HIV positivity\n* Active bacterial, fungal or viral infection \\[except Hepatitis B (HBV patients with active disease who meet the criteria for anti-HBV therapy should be on a suppressive antiviral therapy prior to initiation of cancer therapy) or Hepatitis C virus infections (should have completed curative antiviral treatment with HCV viral load below the limit of quantification\\]\n* Congestive heart failure (as defined by New York Heart Association Functional Classification III or IV), unstable angina, serious uncontrolled cardiac arrhythmia, a myocardial infarction within 6 months prior to study entry or a history of myocarditis\n* Active autoimmune or inflammatory disorder\n* Live vaccines within 30 days prior to enrollment\n* History of organ transplantation\n* History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies)","1 Year","21 Years",{"count":222,"type":22},24,[62],"Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CARE T cells, a new experimental treatment.\n\nThe body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat patients with cancers. They have shown promise, but have not been strong enough to cure most patients.\n\nInvestigators have found from previous research that they can put a new gene (a tiny part of what makes-up DNA and carries a person's traits) into T cells that will make them recognize cancer cells and kill them. In the lab, investigators made several genes called a chimeric antigen receptor (CAR), from an antibody called GPC3. The antibody GPC3 recognizes a protein found solid tumors including pediatric liver cancers. This CAR is called GPC3-CAR. To make this CAR more effective, investigators also added two genes that includes IL15 and IL21, which are protein that helps CAR T cells grow better and stay in the blood longer so that they may kill tumors better. The mixture of GPC3-CAR and IL15 plus IL21 killed tumor cells better in the laboratory when compared with CAR T cells that did not have IL15 plus IL21 .This study will test T cells that investigators made (called genetic engineering) with GPC3-CAR and the IL15 plus IL21 (CARE T cells) in patients with GPC3-positive solid tumors.\n\nT cells made to carry a gene called iCasp9 can be killed when they encounter a specific drug called AP1903. The investigators will insert the iCasp9 and IL15 plus IL21 together into the T cells using a virus that has been made for this study. The drug (AP1903) is an experimental drug that has been tested in humans with no bad side-effects. The investigators will use this drug to kill the T cells if necessary due to side effects.\n\nThis study will test T cells genetically engineered with a GPC3-CAR and IL15 plus IL21 (CARE T cells) in patients with GPC3-positive solid tumors.\n\nThe CARE T cells are an investigational product not approved by the Food and Drug Administration.\n\nThe purpose of this study is to find the biggest dose of CARE T cells that is safe, to see how long they last in the body, to learn what the side effects are and to see if the CARE T cells will help people with GPC3-positive solid tumors.",[30,226,227,228,229,230],"Rhabdomyosarcoma","Malignant Rhabdoid Tumor","Liposarcoma","Wilms Tumor","Yolk Sac Tumor",[232,233,234],"15.21.GPC3-CAR T cells","GPC3","Glypican",{"date":171,"type":43},{"date":237,"type":43},"2024-05-24",{"date":239,"type":22},"2042-07-03",{"name":241,"class":75},"Baylor College of Medicine",{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":18,"minAge":249,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":60,"phases":253,"briefSummary":254,"conditions":255,"keywords":261,"overallStatus":264,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":49},"100641453","transcriptional-pathways-of-surgical-pain-modulated-by-music-therapy-exposure-transpose-100641453","NCT07653594","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE): A Single Arm Pilot Study","Inclusion Criteria:\n\n* Age 50 to 80\n* Able to speak and understand English\n* Scheduled to undergo a surgery meeting the following criteria: (1) traditional open surgery (not laparoscopic or robotic) via laparotomy (midline or subcostal incisions), (2) length of surgery \\>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces\n* Participant reports pain intensity of 4\u002F10 or above to study staff on day 1 post-surgery or any other day post-surgery through discharge\n\nExclusion Criteria:\n\n* Significant visual impairment that has not been corrected\n* Significant hearing impairment that has not been corrected\n* Significant cognitive impairment that would prevent participant from participating in the study","50 Years","80 Years",{"count":252,"type":22},20,[135],"Participants may take part in this study if they are scheduled to undergo a surgery that meets the following: (1) traditional open surgery via laparotomy, (2) length of surgery \\>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces. The purpose of this study is (1) to evaluate the feasibility of collecting blood samples prior to surgery, post-surgery and pre- music-assisted relaxation and imagery (MARI) intervention, and immediately post-MARI intervention and (2) to identify gene expression changes associated with MARI and explore their relationship with immediate changes in pain intensity. Participants will be in this study for the duration of their hospital admission for surgery.",[256,257,258,259,30,260],"Surgery","Stomach Cancer","Pancreas Cancer","Bile Duct Cancer","Peritoneal Cancer",[262,263],"Music therapy","Music-assisted relaxation and imagery","NOT_YET_RECRUITING","2026-08-03",{"date":169,"type":43},{"date":268,"type":22},"2027-01",{"date":270,"type":22},"2027-12",{"name":272,"class":75},"Case Comprehensive Cancer Center",{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":279,"targetDuration":219,"studyType":23,"phases":4,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":264,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":286,"leadSponsor":288,"locationsCount":4},"100650072","development-of-a-risk-prediction-model-for-immune-targeted-therapy-related-diarrhea-in-patients-with-hepatocellular-carcinoma-based-on-tcm-constitutional-types-a-prospective-cohort-study-100650072","NCT07741903","Development of a Risk Prediction Model for Immune-Targeted Therapy-Related Diarrhea in Patients With Hepatocellular Carcinoma Based on TCM Constitutional Types: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Pathologically or radiologically confirmed primary hepatocellular carcinoma (HCC);\n2. Scheduled to receive combined immune checkpoint inhibitor (ICI) and anti-angiogenic targeted therapy;\n3. Aged ≥ 18 years, able to complete questionnaire assessment independently;\n4. Normal hearing, speaking, reading and writing ability; Voluntary participation and signed written informed consent.\n\nExclusion Criteria:\n\n1. Pre-existing underlying intestinal diseases such as chronic diarrhea, inflammatory bowel disease (IBD), or intestinal metastasis before enrollment;\n2. History of long-term laxative use;\n3. Cognitive dysfunction or mental illness that prevents cooperation with questionnaire assessment;\n4. Severe multiple organ failure that precludes completion of full follow-up.",{"count":280,"type":22},500,"Immune checkpoint inhibitors combined with anti-angiogenic targeted agents have become the first-line standard therapeutic regimen for advanced hepatocellular carcinoma (HCC). Nevertheless, the high incidence rate of therapy-related diarrhea severely impairs patients' quality of life and treatment adherence, and may even result in treatment discontinuation. Current studies mostly focus on symptomatic intervention after diarrhea onset, while few tools are available for upfront risk screening prior to treatment initiation. According to the theory of traditional Chinese medicine (TCM) constitutional types, individuals with different constitutions exhibit discrepant disease susceptibility and drug responses. Based on a prospective cohort design, this study aims to explore the correlation between TCM constitutional types and immune-targeted therapy-related diarrhea in HCC patients, and further construct a risk prediction model integrated with both western medical and TCM indicators.\n\nThis study is designed as a multicenter prospective observational cohort study. A total of 350 primary HCC patients receiving combined immunotherapy and targeted therapy at the Affiliated Hospital of Chengde Medical University from January 2027 to December 2028 will be enrolled into the model development cohort. Another 150 patients from Chengde Central Hospital and Chengde Hospital of Traditional Chinese Medicine between January 2029 and January 2030 will be recruited as the external validation cohort. Baseline data will be collected before treatment, including sociodemographic and general clinical information, tumor and treatment-related data, laboratory test results, TCM constitutional assessment, nutritional risk screening, physical function and psychological status evaluation. All participants will be followed up regularly for one year to record the occurrence of diarrhea.\n\nSamples in the development cohort will be randomly divided into a training set and an internal validation set at a stratified ratio of 7:3. Lasso regression will be applied to screen predictive factors, and multivariate Logistic regression will be adopted to establish a nomogram prediction model. Receiver operating characteristic (ROC) curves, calibration curves and decision curve analysis (DCA) will be used to assess the discrimination, calibration and clinical net benefit of the established model, respectively. The independent multicenter data of the external validation cohort will adopt consistent variable criteria, outcome definitions and the prediction model from the development cohort to evaluate the cross-center generalizability, stability and clinical applicability of the model for comprehensive efficacy verification.\n\nThe study protocol has been approved by the Medical Ethics Committee of the Affiliated Hospital of Chengde Medical University. Written informed consent will be obtained from all subjects before enrollment. The research findings will be disseminated via academic journal publications, web-based assessment tools and clinical promotion. The established TCM constitution risk screening tool can be directly applied to routine admission assessment in the hepatology department.",[30],"2026-07-27",{"date":265,"type":43},{"date":268,"type":22},{"date":287,"type":22},"2030-01",{"name":289,"class":75},"Affiliated Hospital of Chengde Medical University",{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":211},"100602476","destiny-pantumour04-100602476","NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","130 Years",{"count":300,"type":22},100,"This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[303,191,304,193,194,195,196,305,199,30,306,307,308,309,200,65,26,310,311,202,312,313,314,315,316,317,318],"Adenocarcinoma (NOS)","Bladder Cancer","Gastrointestinal Stromal Tumour","Melanoma","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Thyroid Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer","2026-07-21",{"date":321,"type":43},"2026-07-22",{"date":323,"type":43},"2025-09-18",{"date":325,"type":22},"2028-03-30",{"name":327,"class":328},"AstraZeneca","INDUSTRY",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":60,"phases":339,"briefSummary":340,"conditions":341,"keywords":343,"overallStatus":264,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":49},"100646449","patients-with-hepatocellular-carcinoma-hcc-100646449","NCT07690683","Patients With Hepatocellular Carcinoma (HCC)","Fecal Microbiota Transplantation as a Response Booster in Patients With Hepatocellular Carcinoma Undergoing Immune Checkpoint Inhibitor Therapy","FORCE","Inclusion Criteria:\n\n* Age \\>18 years;\n* Diagnosis of advanced or unresectable HCC;\n* Patients undergoing standard therapy with immune checkpoint inhibitors (ICIs);\n* Signed informed consent for study participation.\n\nExclusion Criteria:\n\n* Presence of chronic intestinal diseases (e.g., inflammatory bowel disease, celiac disease);\n* Recent use of systemic antibiotics (within the previous 4-6 weeks);\n* Child-Pugh class \\> B8, ECOG performance status \\>1;\n* Any contraindication to colonoscopy.",{"count":338,"type":22},52,[135],"Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide and is frequently diagnosed at an advanced stage, resulting in limited therapeutic options. Despite the advances in immunotherapy, a substantial proportion of patients fail to respond adequately due to mechanisms of immune resistance. The gut microbiota plays a crucial role in modulating the response to immune checkpoint inhibitors (ICIs), and fecal microbiota transplantation (FMT) has demonstrated the ability to enhance their efficacy in other tumors, such as melanoma. In patients with HCC and cirrhosis, intestinal dysbiosis, characterized by a reduction in beneficial bacteria (e.g., Bifidobacterium, Akkermansia) and increased inflammation, is associated with an immunosuppressive profile. Furthermore, a dysbiosis index has been correlated with response to ICIs. In this context, FMT represents a promising strategy to enhance the efficacy of immunotherapy in HCC, although data regarding its efficacy and safety are still limited.",[138,139,342,30],"Liver Diseases",[344,345,346,347],"microbiota","fecal microbiota transplantation","FMT","immunotherapy","2026-07-20",{"date":319,"type":43},{"date":351,"type":22},"2026-09-01",{"date":353,"type":22},"2029-09",{"name":355,"class":75},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":60,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":49},"100477067","unravelling-the-impact-of-radiofrecuency-in-liver-surgery-the-key-to-decrease-local-recurrence-100477067","NCT05492136","Unravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence?","Unravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence? (Study LIVERaTION)","LIVERaTION","Inclusion criteria:\n\n1. Written informed consent granted prior to the initiation of the surgical procedure, given with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.\n2. 18 year of age or older.\n3. WHO performance scale 0-2\n4. Consecutive patients (both sexes equally distributed) suffering from CRLM confirmed either by abdominal CT, abdominal MRI or\u002Fand by histologic-cytological evaluation or patients suffering from HCC.\n5. Any previous chemotherapy regime is permitted.\n6. ASA score 1 to 3.\n\nExclusion criteria:\n\n1. Previous or concurrent cancer that is distinct from one primary tumor of which the Liver metastasis comes from EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis \\& T1).\n2. Any cancer curatively treated \\> 3 years prior to enrollment is permitted.\n3. ASA 4.\n4. Non-resectable extrahepatic metastases.\n5. Liver metastasis from other origin apart from colorectal.\n6. Bening primary tumor of the liver.\n7. Pregnant woman.\n8. Participation in another clinical trial.",{"count":365,"type":22},720,[135],"Radiofrequency devices have been increasingly employed in liver surgery in order to achieve proper hemostasis and this use has become more evident with the implementation of minimal invasive surgery. Due to its well-known efficacy for tumor ablation (i.e. hepatocarcinoma) it use has been extended in some cases to ablate the liver surface after resection in questionable resection. Till date, despite the majority of surgeons apply an additional coagulation in doubtful margins, there is not an evidence that this maneuver really decreases the local recurrence or increases the overall survival. On the contrary, some studies have suggested that non-anatomical resections in order to spare liver parenchyma could lead to major zones of liver ischemia in the remnant liver and thus favoring recurrence. However, major liver ischemia (defined as grade 2 o more) is unlikely to be provoked by 1 cm-depth additional coagulation of the margin.\n\nThe investigators previously published in a retrospective study the concept of additional margin coagulation within liver resections and narrow margins and demonstrated that the study group had significantly less local recurrence compared to the controls. Therefore, in the present study the aim is to continue this evaluation through a multicenter randomized clinical trial.",[30,369],"Cancer, Treatment-Related","2026-07-17",{"date":319,"type":43},{"date":373,"type":43},"2023-11-01",{"date":375,"type":22},"2028-06-30",{"name":377,"class":75},"Hospital del Mar",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":60,"phases":388,"briefSummary":389,"conditions":390,"keywords":392,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":94},"100404407","jump-mr-simulation-for-radiation-therapy-master-protocol-100404407","NCT04545957","Jump: MR Simulation For Radiation Therapy Master Protocol","Judging MR Simulation Procedures: A Phase I-II Study of the Use of Magnetic Resonance Imaging Simulation in the Planning of Radiation Treatments","JUMP","Inclusion Criteria:\n\n* Participants must have a confirmed malignancy requiring radiation therapy.\n* Age: 18 years or older\n* ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)\n* Ability to understand and the willingness to sign a written informed consent document.\n* Disease-specific eligibility criteria will be specified in the appropriate subprotocol.\n\nExclusion Criteria:\n\n* For MRI involving contrast, history of allergic reactions attributed to gadolinium based IV contrast. Note: If patient will not receive contrast, this is not applicable\n* Participants who cannot undergo an MRI\n* Disease-specific exclusion criteria will be specified in the appropriate subprotocol",{"count":387,"type":22},86,[135],"This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.",[26,391,30,199],"Recurrent Adenocarcinoma",[26,391,30,199],{"date":348,"type":43},{"date":395,"type":43},"2020-10-14",{"date":397,"type":22},"2030-10-22",{"name":399,"class":75},"Brigham and Women's Hospital",{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":406,"targetDuration":408,"studyType":23,"phases":4,"briefSummary":409,"conditions":410,"keywords":411,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":437},"100648032","dragon-registry---international-multicenter-registry-and-medical-image-bank-for-patients-with-primarily-unresectable-liver-cancer-or-liver-metastases-that-underwent-combined-portal-and-hepatic-vein-embolization-pvehve-to-increase-future-liver-remnant-before-resection-100648032","NCT07717437","DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE\u002FHVE) to Increase Future Liver Remnant Before Resection.","Inclusion Criteria:\n\n* Patients who have undergone PVE\u002FHVE or technical variations on this procedure\n* 18 Years and older\n* Men and women",{"count":407,"type":22},350,"5 Years","The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE\u002FHVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE. This collaborative registry focuses on identifying associations between baseline clinical\u002Fimaging parameters, clinical outcomes, and safety for patients undergoing PVE\u002FHVE.",[30,141],[165,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,138,427,428],"Liver metastases","Portal vein embolization","PVE","HVE","PVE\u002FHVE","Future liver remnant","Liver resection","Hepatectomy","Post-hepatectomy liver failure","Surgical oncology","Double Vein Embolisation","FLR","Liver Venous Deprivation","LVD","Hepatic Vein Embolization","Perihilar cholangiocarcinoma","Intrahepatic cholangiocarcinoma","2026-07-16",{"date":319,"type":43},{"date":432,"type":43},"2021-03-16",{"date":434,"type":22},"2032-11-30",{"name":436,"class":75},"Maastricht University Medical Center",31,{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":60,"phases":447,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":468,"locationsCount":49},"100560657","phase-2-repurposing-riluzole-for-cancer-related-cognitive-impairment-a-pilot-trial-100560657","NCT06580002","Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial","Repurposing Riluzole for Augmenting Brain-Derived Neuropathic Factor (BDNF) Levels and Cognitive Function in Patients Experiencing Cancer-Related Cognitive Impairment: An Interventional Pilot Clinical Trial","Inclusion Criteria:\n\n1. Cohort-specific inclusion for male and female patients.\n\n   a. Cohort A (no prior cranial radiation) i. Diagnosed with one of the following:\n   * Breast cancer exposed to treatment including chemotherapy, radiotherapy, surgery and\u002For other breast cancer interventions.\n   * Non-breast cancer patients exposed to anthracyclines- or platinum-containing chemotherapy within the past 3 years.\n   * Non-breast cancer patients exposed to other anticancer therapies within the past 3 years.\n\n     b. Cohort B (prior cranial radiation)\n   * Previously received radiotherapy or radiosurgery to the brain for benign, malignant, or metastatic tumors.\n   * Life expectancy \\> 6 months\n2. Washout from investigational and conventional interventions is up to the discretion of the investigator. Concurrent participation in another intervention is allowable if judged by the Principal Investigator that this would not be scientifically or medically incompatible with this study.\n3. ≥18 years of age\n4. Perceived by patient or investigator that cognitive function has worsened since receipt of cranial radiation or cancer treatment.\n5. Able to provide informed consent.\n6. Literacy in English, Chinese, Korean, Vietnamese, or Spanish, to complete the questionnaires.\n7. Patients must agree to complete and be able to complete the questionnaires and computerized assessments used to measure functional outcomes.\n\n   * Note: Patients who have visual impairment or have degenerative conditions (e.g. Parkinsons's disease, etc.) can participate if they cannot complete computerized assessments, as long as they can still complete the questionnaires with assistance.\n\nExclusion Criteria:\n\n1. Cohort-specific exclusion for male and female patients:\n\n   1. Cohort A (no prior cranial radiation)\n\n      * History of or current presence of primary brain tumors or brain metastases.\n   2. Cohort B (prior cranial radiation)\n\n      * Diagnosed with high grade glioma.\n2. Unwilling to undergo neuropsychological assessments necessary for the study.\n3. Women who are breastfeeding, pregnant or are planning to get pregnant during the study period. Persons of child-bearing potential (POCBP) must have a negative pregnancy test at screening if there is suspicion of pregnancy.\n\n   a. Female patients who are considered not to be of childbearing potential must have a history of being postmenopausal (with a minimum of 1 year without menses), tubal ligation, or hysterectomy.\n4. History of suspected hypersensitivity to riluzole or to any of its excipients.\n5. Patients taking or planned to take medications\u002Fsubstances with potential drug-drug interactions: pixantrone, current smoker (defined as having smoked within the last month), abametapir, cannabis, capmatinib, lapatinib, methotrexate, and levoketoconazole.\n6. Hepatic impairment as indicated by: AST or ALT ≥ 3x upper limit normal (ULN)\n7. Have serious pre-existing medical conditions that, in the judgment of the investigator, would preclude participation in this study.",{"count":446,"type":22},75,[448],"PHASE2","This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole brain radiation for benign or malignant tumors with cancer related cognitive impairment.",[27,202,197,29,199,451,200,30,452,453,454,455,456,457,26,258,458,459,460,306,461,198],"Colorectal Cancer","Genitourinary Cancer","Gynecologic Cancer","Urinary Bladder Cancer","Leukemia","Lymphoid Leukemia","Myeloma Multiple","Non-hodgkin Lymphoma","Hodgkin Lymphoma","Brain Cancer","Mycosis Fungoides","2026-07-11",{"date":464,"type":43},"2026-07-14",{"date":466,"type":43},"2024-12-02",{"date":270,"type":22},{"name":469,"class":75},"University of California, Irvine",{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":492},"100454570","multi-analyte-blood-test-clinical-trial-100454570","NCT05199259","Multi-analyte Blood Test Clinical Trial","Collection of Blood to Evaluate Epigenomics and Protein Biomarkers for the Detection of Hepatocellular Carcinoma","LIVER-1","Inclusion Criteria:\n\n* Age 18 years or older.\n* Males and Females.\n* Having cirrhosis or meeting the AASLD guidelines for HCC\n* surveillance.\n* Clinically diagnosed with HCC or negative for HCC following disease\n* surveillance.\n* HCC positive Group: Subject has a recent (within 6 months of enrollment) clinically diagnosed, untreated hepatocellular carcinoma as defined by at least one ≥1 cm lesion exhibiting arterial phase hyperenhancement in combination with washout appearance and\u002For capsule by 4 phase CT scan or multiphase contrast enhanced MRI or biopsy is positive for HCC.\n* HCC negative Group: Non-cancer, at-risk subjects with chronic liver disease undergoing routine imaging surveillance for HCC, where the definitive lack of HCC within 3 months prior to enrollment has been verified by negative imaging, for HCC. No more than 200 subjects without cirrhosis can be enrolled in this group.\n* Sub-Group 1 (approximately 450 subjects) - negative by CT or MRI (No lesion, LR-1 or LR-2)\n* Sub-Group 2 (approximately 450 subjects) - negative by ultrasound\n\nExclusion Criteria:\n\n* Subjects that are unwilling or unable to sign the Informed Consent Form will be excluded.\n* Known cancer diagnosis of a cancer other than HCC within the past 5 years (with the exceptions of basal cell or squamous cell skin cancers).\n* Chemotherapy and\u002For radiation therapy within 5 years prior to enrollment\u002Fsample collection.\n* Prior or current treatment with sorafenib, regorafenib, or other treatment indicated for HCC.\n* Prior treatment with a DNA methyltransferase inhibitor such as with Vidaza (azacitidine) or Dacogen (decitabine)\n* Any HCC treatment prior to enrollment\u002Fblood sample collection (e.g., surgery, ablation, embolization, pharmacotherapy, radiotherapy, liver transplant or other treatment indicated for HCC).\n* IV contrast (e.g., CT and MRI) within 1 day \\[or 24 hours\\] of blood collection.\n* Less than 3 days between fine needle aspiration (FNA) of target pathology and blood collection.\n* Less than 7 days between biopsy (other than FNA) of target pathology and blood collection.\n* Any condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.\n* For HCC negative subjects, patients with a prior diagnosis of HCC are also excluded.\n* Subjects that are pregnant will be exclude",{"count":479,"type":22},1200,"The objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance. These samples will be used for research purposes to develop and validate the Helio multi-analyte blood test.",[110,30,482,138],"HCC","2026-07-09",{"date":485,"type":43},"2026-07-10",{"date":487,"type":43},"2022-03-01",{"date":489,"type":22},"2028-12",{"name":491,"class":328},"Helio Genomics",7,{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":500,"targetDuration":4,"studyType":60,"phases":502,"briefSummary":503,"conditions":504,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":515,"lastUpdatePostDateStruct":516,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":49},"100619216","phase-1-sl-28-for-advanced-solid-tumours-100619216","NCT07341737","SL-28 for Advanced Solid Tumours","A Phase 1\u002F2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours","Inclusion Criteria:\n\n* Ability to provide written informed consent prior to any study-related procedures and to understand the nature, purpose, and potential risks of the study\n* Adult males and females ≥18 years of age at screening\n* Life expectancy of at least 3 months\n* Histologically or cytologically confirmed unresectable advanced solid tumor (recurrent, metastatic, or locally advanced)\n* Disease refractory to, intolerant of, or refusal of standard therapies, including immunotherapy and molecular\u002Fbiomarker-directed treatments, as determined by the Principal Investigator (PI) or delegate\n* Eligible tumor types include:\n* Head and neck squamous cell carcinoma\n* Thoracic malignancies (small-cell lung cancer, non-small cell lung cancer, esophageal cancer)\n* Gastrointestinal malignancies (gastric, liver, colorectal, pancreatic adenocarcinoma)\n* Genitourinary malignancies (bladder, renal cell, prostate cancer)\n* Gynecologic malignancies (ovarian, endometrial cancer)\n* Breast cancer and melanoma\n* Evaluable disease per RECIST v1.1\n* ECOG performance status 0-1 (or up to 2 at PI discretion)\n* Adequate organ function, defined as:\n* Total bilirubin ≤1.5 × ULN (≤2.0 × ULN for liver metastases or Gilbert's syndrome)\n* AST, ALT, alkaline phosphatase ≤2.5 × ULN (≤5 × ULN if liver metastases, at PI discretion)\n* Creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault) or eGFR ≥50 mL\u002Fmin (CKD-EPI)\n* Absolute neutrophil count ≥1,000\u002Fmm³\n* Platelet count ≥100,000\u002Fmm³\n* Hemoglobin ≥90 g\u002FL without transfusion within 2 weeks\n* Prothrombin time and aPTT ≤1.5 × ULN (or stable INR if on anticoagulation)\n\nFemale patients:\n\n-Non-childbearing potential (surgically sterile or postmenopausal), or of childbearing potential with negative pregnancy tests and agreement to effective contraception through 90 days post-dose\n\nMale patients:\n\n* Agreement not to donate sperm for 90 days post-dose\n* Agreement to use adequate contraception as applicable\n* Suitable venous access for blood sampling\n* Willingness and ability to comply with study procedures and protocol requirements\n\nExclusion Criteria:\n\n* Ongoing toxicities ≥ Grade 2 per NCI CTCAE v5.0 (except alopecia, fatigue, sensory neuropathy, or adequately treated endocrine deficiencies)\n* NYHA Class III or IV heart disease, myocardial infarction within 6 months, unstable arrhythmia, or ischemia on ECG\n* QTcF \\>470 ms (females) or \\>450 ms (males)\n* Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy\n* Requirement for systemic corticosteroids or other immunosuppressive therapy that cannot be discontinued ≥14 days prior to dosing\n* Prior therapies within restricted timeframes:\n* Immune checkpoint inhibitors or biologics within 28 days\n* Antineoplastic therapies, surgery, radiotherapy, or radiopharmaceuticals within 21 days\n* Unapproved investigational drugs within 5 half-lives\n* Nitrosoureas or mitomycin C within 6 weeks\n* Concurrent malignancy within 5 years, except specified low-risk cancers\n* Pregnancy or breastfeeding\n* Known HIV, hepatitis B (HBsAg positive), or hepatitis C infection\n* Inability or unwillingness to comply with protocol procedures\n* History of anaphylaxis or significant allergy interfering with participation\n* Clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, neurologic, psychiatric, or immunologic disease within 6 months\n* Conditions affecting drug absorption, distribution, metabolism, or excretion\n* Receipt of live vaccines within 28 days prior to screening\n* Participation in another investigational study within 30 days prior to screening",{"count":501,"type":22},60,[62,448],"Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.",[505,506,507,508,509,510,195,511,30,512,304,513,26,514,27,200,194,451],"Head & Neck Cancer","Pancreas Carcinoma","Pancreas Cancer, Metastatic","Lung Adenocarcinoma","Lung Cancer (NSCLC)","Lung Cancer (Non-Small Cell)","Stomach (Gastric) Cancer","Intestinal Cancer","Renal Cancer","Melanoma (Skin Cancer)","2026-07-08",{"date":485,"type":43},{"date":518,"type":22},"2026-07-13",{"date":520,"type":22},"2027-03-01",{"name":522,"class":328},"Second Life Therapeutics",{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":17,"sex":18,"minAge":530,"maxAge":531,"enrollmentInfo":532,"targetDuration":4,"studyType":60,"phases":534,"briefSummary":535,"conditions":536,"keywords":4,"overallStatus":264,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":545,"locationsCount":4},"100644984","precision-navigation-to-improve-community-cancer-screening-participation-100644984","NCT07676383","Precision Navigation to Improve Community Cancer Screening Participation","Effectiveness and Mechanisms of a Precision Navigation Intervention to Improve Community Cancer Screening Participation: A Dual-Cohort Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 45 to 74 years.\n2. Permanent resident of a participating community, defined as having lived in the community for at least 6 months during the past 12 months.\n3. Participating in the urban cancer screening program.\n4. Identified by the program risk assessment questionnaire as being at high risk for at least one of the following cancers: lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer.\n5. Has not yet completed the corresponding free clinical screening test for the high-risk cancer type or types.\n6. Able to complete electronic questionnaires and read intervention materials independently or with assistance. Paper materials and staff explanation will be provided for participants who do not use smartphones.\n7. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Previously diagnosed with any of the target cancers, including lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer.\n2. Severe cognitive impairment, severe mental illness, or other conditions that prevent the participant from receiving the intervention or completing study questionnaires.\n3. Planning to be away from the community for a long period during the next 6 months, defined as cumulative absence of more than 3 months.\n4. Currently participating in another interventional study that may affect cancer screening behavior.","45 Years","74 Years",{"count":533,"type":22},1500,[135],"This study will evaluate whether a precision navigation intervention can help community residents at high risk for cancer complete recommended cancer screening. The study will be conducted in communities participating in an urban cancer screening program in China.\n\nEligible participants will be adults aged 45 to 74 years who are permanent residents of participating communities and have been identified as being at high risk for at least one of five cancers: lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer. Participants must not have completed the corresponding free clinical screening before enrollment.\n\nThis is a dual-cohort, cluster randomized controlled trial. Communities, rather than individual participants, will be assigned to one of three groups: a precision navigation group, a usual health education group, or a waiting control group. Participants will be classified into two cohorts according to the number of cancers for which they are assessed as high risk. Cohort A will include participants at high risk for three or more cancers, and Cohort B will include participants at high risk for one or two cancers.\n\nParticipants in the precision navigation group will receive a personalized navigation report matched to their risk profile. The report will explain the screening tests most relevant to them, help them understand screening choices, and provide practical steps to support screening completion. Participants in the usual health education group will receive general cancer screening education materials. Participants in the waiting control group will not receive active screening promotion during the main intervention period, but will receive general education materials after the primary assessment.\n\nThe main outcome is whether participants complete the recommended cancer screening during follow-up. The study will also assess changes in screening-related decision conflict, anxiety, self-efficacy, and behavioral intention.\n\nThe results may help improve community-based cancer screening programs and provide evidence for using personalized navigation strategies to increase screening participation among high-risk populations.",[537,29,27,451,538,30],"Cancer Screening","Upper Gastrointestinal Cancer","2026-07-07",{"date":515,"type":43},{"date":542,"type":22},"2026-06",{"date":544,"type":22},"2027-02",{"name":546,"class":75},"Hunan Cancer Hospital",{"id":548,"slug":549,"hasResults":12,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":553,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":18,"minAge":219,"maxAge":220,"enrollmentInfo":555,"targetDuration":4,"studyType":60,"phases":557,"briefSummary":558,"conditions":559,"keywords":565,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":578,"locationsCount":580},"100411195","phase-1-et140203-t-cells-in-pediatric-subjects-with-hepatoblastoma-hcn-nos-or-hepatocellular-carcinoma-100411195","NCT04634357","ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma","An Open-Label, Dose Escalation, Phase I\u002FII Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed\u002FRefractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)","ARYA-2","Inclusion Criteria:\n\n1. Histologically confirmed HB, HCN-NOS, or HCC with serum AFP \\>100ng\u002FmL at the time of screening and following the most recent line of therapy.\n2. Disease recurrence after remission following initial standard-of care (SOC) treatment (i.e., relapse) or failure of response to SOC treatment (i.e., refractory).\n3. Age ≥ 1 year and ≤ 21 years.\n4. Molecular Human Leukocyte Antigen (HLA) class I allele typing that confirms subject carries at least one HLA-A2 allele.\n5. Life expectancy of \\> 4 months per the Investigator's opinion.\n6. Lansky or Karnofsky Performance Scale ≥ 70.\n7. For enrollment to the dose-finding cohort, subjects must have at least one (1) lesion ≥ 5 mm in diameter or two (2) or more lesions ≥ 3 mm in diameter. For the dose-expansion cohort, subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n8. Child-Pugh score of A6 or better.\n9. Adequate organ function.\n\nExclusion Criteria:\n\n1. Recurrent HB who are candidates for complete surgical resection (e.g., isolated pulmonary relapse amendable to pulmonary metastasectomy).\n2. Pre-existing illness including heart failure, uncontrolled pulmonary disease not cancer-related, or psychiatric illness\u002Fsocial situation that would limit compliance with study requirements.\n3. Active, uncontrolled systemic bacterial, fungal, or viral infection. Subjects with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C are eligible provided their infection is being treated and the viral load is controlled.\n4. Any known active malignancy (other than HB, HCN-NOS, or HCC).\n5. Pregnant or lactating women.\n6. Received the following within one (1) week of leukapheresis or within two (2) weeks of conditioning chemotherapy: cytotoxic chemotherapy, radiation, other anti-cancer therapies (including immunotherapeutic agents), or immunosuppressive therapy. Systemic corticosteroids at doses greater than 5 mg\u002Fday of prednisone or equivalent doses of other corticosteroids within two (2) weeks prior to leukapheresis or conditioning chemotherapy or receipt of a T-cell engager (TCE) within two (2) months prior to leukapheresis or at any time as bridging therapy between leukapheresis and conditioning chemotherapy is exclusionary. (Note: Topical and inhaled corticosteroids in standard doses and physiological replacement doses of corticosteroids for adrenal insufficiency are allowed).\n7. Concurrently receiving other investigational agents, biological, chemical, or radiation therapies, while participating in the study.\n8. Contraindication for receipt of conditioning chemotherapeutic agents including Fludarabine and Cyclophosphamide.\n9. Active autoimmune disease requiring systemic immunosuppressive therapy.\n10. Compromised circulation in the main portal vein, hepatic vein, or vena cava due to partial or complete obstruction which, in the opinion of the Investigator, would make the subject unsuitable for the study.\n11. History of organ transplant.\n12. HB, HCN-NOS, or HCC involving greater than 50% of the liver (volumetric).",{"count":556,"type":22},12,[62,448],"Open-label, dose escalation, multi-center, Phase I\u002FII clinical trial to assess the safety\u002Ftolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive\u002FHLA-A2-positive and have relapsed\u002Frefractory HB, HCN-NOS, or HCC.",[560,561,562,563,30,564],"Hepatoblastoma","Hepatocellular Carcinoma (HCC)","Liver Neoplasms","Metastatic Liver Cancer","HEMNOS",[566,567,568,561,30,569,563,570,564],"Relapsed\u002FRefractory Hepatoblastoma (HB)","Pediatric","Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS)","T-cell therapy","Liver neoplasms","2026-07-01",{"date":573,"type":43},"2026-07-06",{"date":575,"type":43},"2022-07-19",{"date":577,"type":22},"2028-01-31",{"name":579,"class":328},"Eureka Therapeutics Inc.",4,{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":102,"enrollmentInfo":588,"targetDuration":4,"studyType":60,"phases":590,"briefSummary":591,"conditions":592,"keywords":4,"overallStatus":264,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":4},"100647027","phase-2-haic--deb-tace--toripalimab--lenvatinib-for-unresectable-intrahepatic-cholangiocarcinoma-100647027","NCT07685535","HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma","Hepatic Arterial Infusion Chemotherapy (HAIC) Sequential Small-Sized Drug-Eluting Beads Transarterial Chemoembolization (DEB-TACE) Combined With Toripalimab and Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma: A Phase II Clinical Study","Inclusion Criteria:\n\n1. Voluntary participation and signed informed consent.\n2. Age 18 to 85 years.\n3. Pathologically confirmed intrahepatic cholangiocarcinoma.\n4. Imaging-confirmed unresectable locally advanced intrahepatic cholangiocarcinoma with measurable lesions (longest diameter ≥10 mm) per RECIST 1.1.\n5. No distant organ metastases (excluding lymph node metastases).\n6. Child-Pugh liver function grade A or good B (≤7 points).\n7. ECOG performance status score 0-1 within 1 week before enrollment.\n8. Expected survival ≥12 weeks.\n9. No prior treatment with immune checkpoint inhibitors (including PD-1\u002FPD-L1 antibodies and CTLA-4 inhibitors).\n10. Laboratory values within 7 days before enrollment meeting the following criteria:\n\nANC ≥1.0×10⁹\u002FL; platelets ≥50×10⁹\u002FL; hemoglobin ≥90 g\u002FL (without transfusion or G-CSF within 14 days before screening).\n\nSerum albumin ≥30 g\u002FL; total bilirubin ≤1.5×ULN; ALT and AST ≤5×ULN; serum creatinine ≤1.5×ULN or CrCl \\>50 mL\u002Fmin (Cockcroft-Gault formula).\n\nINR ≤2.3 or PT prolonged ≤6 seconds above normal range.\n\nUrine protein \\\u003C2+ (if ≥2+, 24-hour quantification \\\u003C1.0 g allowed).\n\nExclusion Criteria:\n\n1. Received other local treatments (excluding surgery) within 1 month before study entry. Prior TAE\u002FTAI not allowed. Prior TACE \\>3 times not allowed.\n2. Prior systemic anti-tumor therapy (including targeted therapy, immunotherapy, chemotherapy).\n3. Concurrent or prior other malignancy within 5 years.\n4. Active autoimmune disease or history of autoimmune disease with potential relapse.\n5. Clinically symptomatic moderate-to-severe ascites requiring therapeutic paracentesis\u002Fdrainage or Child-Pugh score \\>2; uncontrolled or moderate-to-large pleural\u002Fpericardial effusion.\n6. History of abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months before study treatment.\n7. History of thrombosis or embolic events (e.g., cerebrovascular accident including TIA, cerebral hemorrhage, cerebral infarction, pulmonary embolism) within 6 months before study treatment.\n8. Known inherited or acquired bleeding disorder or thrombotic tendency; currently or recently (within 10 days) receiving full-dose anticoagulants or thrombolytics for therapeutic purposes (prophylactic low-dose aspirin or LMWH allowed).\n9. Major vascular disease within 6 months before study treatment (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis).\n10. Severe, non-healing, or dehisced wounds, active ulcers, or untreated fractures.\n11. Major surgery within 4 weeks before study treatment (excluding diagnostic) or anticipated need for major surgery during the study.\n12. History of intestinal obstruction or clinical signs\u002Fsymptoms of GI obstruction within 6 months before study treatment.\n13. History of hepatic encephalopathy.\n14. Palliative radiotherapy for non-target lesions allowed only if completed ≥2 weeks before study treatment and AEs recovered to ≤CTCAE grade 1.\n15. Severe infection within 4 weeks before study treatment, including hospitalization for infection, bacteremia, or severe pneumonia; oral or IV therapeutic antibiotics within 2 weeks (prophylactic allowed).\n16. Congenital or acquired immunodeficiency (e.g., HIV infection).\n17. Palliative radiotherapy involving \\>5% of bone marrow area within 4 weeks for patients with bone metastases.\n18. Received live attenuated vaccine within 28 days before study treatment, or expected to receive such vaccine during toripalimab treatment or within 60 days after last dose.\n19. Received other investigational drugs within 28 days before study treatment.\n20. Other factors judged by the investigator that may affect study results or cause premature termination, such as alcoholism, drug abuse, other serious diseases (including psychiatric) requiring concomitant treatment, severe laboratory abnormalities, family or social factors affecting patient safety.",{"count":589,"type":22},29,[448],"Purpose: This phase II clinical trial evaluates whether a combination of liver-directed local therapies (HAIC and DEB-TACE) with immunotherapy (toripalimab) and targeted therapy (lenvatinib) is safe and effective for patients with unresectable intrahepatic cholangiocarcinoma (a type of liver cancer that cannot be removed by surgery).\n\nParticipants: Adults aged 18-85 years with pathologically confirmed unresectable intrahepatic cholangiocarcinoma, no prior immune checkpoint inhibitor therapy, and adequate organ function.\n\nStudy details include:\n\nStudy Duration: Up to 24 months per participant\n\nTreatment Duration: Up to 6 cycles (each cycle is 21 days) of combination therapy, followed by maintenance therapy with toripalimab and lenvatinib until disease progression or unacceptable toxicity\n\nVisit Frequency: Every 3 weeks during the treatment phase; tumor imaging assessments every 6-8 weeks\n\nPrimary endpoints: Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Safety will be assessed by monitoring adverse events graded according to NCI-CTCAE v5.0.\n\nToripalimab and lenvatinib are not available through an expanded access program.",[30],"2026-06-28",{"date":573,"type":43},{"date":596,"type":22},"2026-06-30",{"date":598,"type":22},"2028-12-31",{"name":600,"class":75},"Shanghai Zhongshan Hospital",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":609,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":611,"conditions":612,"keywords":620,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":637},"100618120","predicting-response-to-immunotherapy-from-analysis-of-live-tumor-biopsies-elephas-05-100618120","NCT07327489","Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)","Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies","ELEPHAS-05","Inclusion Criteria:\n\n1. Able and willing to provide informed consent for participation\n2. Age ≥18 years at time of consent.\n3. Have a suspected or confirmed cancer diagnosis that is to be evaluated by means of a biopsy.\n4. Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment.\n\nExclusion Criteria:\n\n1. Have a known auto-immune disease or prior condition (prior organ transplant, chronic kidney or liver disease) that renders them ineligible for immunotherapy (IO) treatment.\n2. Severely immunocompromised person(s). Examples include patients on immunosuppressants, HIV positive patients on antiretrovirals, post transplantation patients.\n3. Pregnant person(s).",{"count":610,"type":22},2000,"This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.",[36,613,614,304,615,451,616,617,194,199,198,30,618,619,514],"Immunotherapy","Advanced Solid Tumors Cancer","TNBC, Triple Negative Breast Cancer","DMMR Colorectal Cancer","MSI-H Colorectal Cancer","NSCLC (Non-small-cell Lung Cancer)","Skin Cancer",[613,621,622,36,623,624,625,626,627,628],"Live Tumor Biopsy","Elephas","Imaging","Tumor Cutting","Treatment Response","Core Needle Biopsy","Forceps Biopsy","Punch Biopsy","2026-06-25",{"date":631,"type":43},"2026-06-29",{"date":633,"type":43},"2025-04-14",{"date":635,"type":22},"2038-04",{"name":622,"class":328},8,{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":642,"acronym":643,"eligibilityCriteria":644,"healthyVolunteers":17,"sex":18,"minAge":645,"maxAge":646,"enrollmentInfo":647,"targetDuration":250,"studyType":23,"phases":4,"briefSummary":649,"conditions":650,"keywords":677,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":687,"startDateStruct":688,"completionDateStruct":690,"leadSponsor":692,"locationsCount":694},"100210159","integrated-cancer-repository-for-cancer-research-100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals","19 Years","110 Years",{"count":648,"type":22},999999,"The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[65,315,29,195,651,28,201,652,191,259,653,654,197,30,655,656,657,658,304,198,659,26,313,660,316,661,662,663,664,665,666,667,668,311,619,669,670,671,27,455,306,202,672,673,200,194,317,674,675,676],"Thymus Cancer","Gastrointestinal Stromal Tumors","Duodenal Cancer","Gallbladder Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Penile Cancer","Ureter Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Unknown Primary Tumor","Multiple Myeloma","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[65,315,678,679,680,681,682,683,684,685,27,686,675,676],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor",{"date":631,"type":43},{"date":689,"type":43},"2013-11-01",{"date":691,"type":22},"2099-12",{"name":693,"class":75},"University of Nebraska",42,{"id":696,"slug":697,"hasResults":12,"nctId":698,"briefTitle":699,"officialTitle":700,"acronym":701,"eligibilityCriteria":702,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":703,"targetDuration":4,"studyType":60,"phases":705,"briefSummary":706,"conditions":707,"keywords":715,"overallStatus":264,"whyStopped":4,"lastUpdateSubmitDate":725,"lastUpdatePostDateStruct":726,"startDateStruct":728,"completionDateStruct":729,"leadSponsor":731,"locationsCount":94},"100641147","digitally-supported-prehabilitation-before-major-visceral-cancer-surgery-100641147","NCT07658313","Digitally Supported Prehabilitation Before Major Visceral Cancer Surgery","From Prehabilitation to Rehabilitation: A Feasibility Trial for Digitally Supported Prehabilitation in Major Visceral Oncologic Surgery","P2R-OncoVis","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Clinical diagnosis requiring major surgery of the pancreas, liver, bile ducts, stomach, or esophagus with curative intent\n* Confirmed indication for surgery by the multidisciplinary tumor board\n* Medical stability and physician clearance to participate in a prehabilitation exercise program\n* Willingness and ability to attend center-based prehabilitation exercise sessions three times per week, or once per week with additional tele-prehabilitation if travel time exceeds 40 minutes one way\n* Willingness and ability to perform home-based physical activities\n* Sufficient German language proficiency and digital literacy\n* Access to a smartphone or tablet device with internet connection\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Physical disability or mental impairment preventing safe participation in the study\n* Health care medical power of attorney not permitting independent consent\n* Non-elective, emergency, or revision surgery\n* Acute medical condition contraindicating participation in a structured prehabilitation program",{"count":704,"type":22},30,[135],"Major visceral oncologic surgery is associated with high postoperative morbidity, prolonged hospitalization, delayed recovery, and reduced quality of life. Patients undergoing surgery of the pancreas, liver, bile ducts, stomach, or esophagus frequently present with reduced physical fitness, malnutrition, sarcopenia, and psychological distress, all of which may negatively affect surgical outcomes and rehabilitation. Although prehabilitation has shown potential to improve functional capacity before surgery, structured prehabilitation pathways are currently not routinely implemented in Austria, and the feasibility of digitally supported perioperative care pathways remains insufficiently evaluated.\n\nThe aim of the Prehab2Rehab-OncoVis study is to evaluate the feasibility, acceptability, and safety of a multimodal, digitally supported prehabilitation intervention for patients undergoing major visceral oncologic surgery with curative intent. The study will additionally explore potential effects on clinical recovery, functional capacity, rehabilitation outcomes, and patient-reported outcomes across the perioperative pathway.\n\nPrehab2Rehab-OncoVis is designed as a prospective, single-arm feasibility cohort study conducted at the University Hospital Salzburg and the University Institute of Sports Medicine, Prevention and Rehabilitation, coordinated by the Paracelsus Medical University in cooperation with the Ludwig Boltzmann Institute for Rehabilitation Research and the Ludwig Boltzmann Institute for Digital Health and Prevention within the Prehab2Rehab consortium. Approximately 30 adult patients, with the possibility to include up to 50 participants if feasible, will be consecutively recruited.\n\nThe intervention consists of a four-week multimodal prehabilitation program combining supervised exercise training, promotion of physical activity, nutritional counseling, psycho-oncological distress screening, and health literacy support. Digital tools will support the intervention throughout the perioperative pathway, including the HERO application (Das Herz Reha-Informationstool) for patient education and health literacy, aktivplan as a digital exercise planner and training diary, and the CAATS telecommunication platform for remote supervision and tele-prehabilitation sessions where appropriate.\n\nThe exercise intervention includes supervised center-based sessions and, for participants with longer travel distances, a hybrid model combining center-based and tele-prehabilitation sessions. Nutritional counseling will follow current European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines and includes screening for malnutrition risk. Psycho-oncological distress screening will follow recommendations of the German Cancer Society and includes referral to supportive care when clinically indicated.\n\nParticipants will be assessed throughout the perioperative pathway, including at the beginning and end of prehabilitation (Prehabilitation Assessment 1 \\[PRE1\\] and Prehabilitation Assessment 2 \\[PRE2\\]), during hospitalization and rehabilitation, and at a three-month follow-up after surgery. Primary outcomes focus on feasibility, including recruitment and retention rates, adherence, fidelity, safety, data management feasibility, and acceptability and usability of the digital technologies. Secondary outcomes include clinical recovery indicators, postoperative complications, length of hospital and intensive care stay, functional independence, psychological well-being, quality of life, body composition, cardiorespiratory fitness, functional exercise capacity, and muscle strength.\n\nTo contextualize outcomes, two historical comparator cohorts will be used: a local hospital cohort of patients who previously underwent similar surgery without prehabilitation, and a national rehabilitation cohort derived from routine rehabilitation datasets matched for diagnosis, sex, and age.\n\nThe study is intended to generate feasibility data and preliminary estimates that may support the development of future adequately powered randomized controlled trials evaluating digitally supported prehabilitation and rehabilitation pathways in visceral oncologic surgery.",[708,709,710,711,712,65,30,713,714],"Gastrointestinal Neoplasms","Pancreatic Neoplasms","Liver Neoplasm","Oesophageal Cancer","Gastrointestinal Cancer","Prehabilitation","Cancer Rehabilitation",[713,716,717,718,719,720,721,722,723,724],"Visceral Surgery","Oncology","Rehabilitation","Digital Health","Exercise Therapy","Teleprehabilitation","Cancer Surgery","Preoperative Care","Functional Recovery","2026-06-16",{"date":727,"type":43},"2026-06-18",{"date":542,"type":22},{"date":730,"type":22},"2027-07",{"name":732,"class":75},"Ludwig Boltzmann Institute for Digital Health and Prevention",{"id":734,"slug":735,"hasResults":12,"nctId":736,"briefTitle":737,"officialTitle":738,"acronym":739,"eligibilityCriteria":740,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":741,"targetDuration":4,"studyType":60,"phases":742,"briefSummary":743,"conditions":744,"keywords":747,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":771,"lastUpdatePostDateStruct":772,"startDateStruct":774,"completionDateStruct":776,"leadSponsor":778,"locationsCount":49},"100604152","phase-2-y-90-treatment-response-using-transarterial-radioembolization-100604152","NCT07145801","Y-90 Treatment Response Using Transarterial Radioembolization","Contrast-Enhanced Ultrasound Evaluation of Radioembolization Treatment Response","TARE","Inclusion Criteria:\n\n* Scheduled for TARE therapy of a treatment naïve HCC visible on ultrasound.\n* Be at least 18 years of age.\n* Be medically stable.\n* If a female of child-bearing age, must have a negative pregnancy test.\n* Have signed Informed Consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable.\n* Patients with known sensitivities to the components of Lumason.\n* Patients with known sensitivities to the components of Sonazoid.",{"count":704,"type":22},[448],"This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE). HCC is the third leading cause of cancer mortality worldwide and the single fastest growing cause of cancer mortality in the United States. TARE is recommended for 15-25% of HCC patients. Treatment response is generally evaluated using contrast-enhanced CT or MRI 1-2 months and 4-6 months post-TARE. Although TARE is an effective therapy, assessment of treatment response using CT\u002FMRI is challenging because CT\u002FMRI frequently diagnoses tumor response as equivocal or non-progressing for up to 6 months post-TARE based on LI-RADS criteria. This delay in diagnosing tumor viability subsequently delays needed retreatment and can even serve as a barrier to transplantation. Our prior work in HCC locoregional therapy has shown CEUS provides improved sensitivity in detecting viable tumor following transarterial chemoembolization relative to traditional CT\u002FMRI. Therefore, the investigators propose to evaluate both qualitative and quantitative CEUS as a tool for evaluating HCC post-TARE at similar time points of clinically recommended cross-sectional imaging, while also investigating the role of Kupffer phase imaging.\n\nThe investigators plan to enroll a total of 30 patients scheduled for TARE of a treatment naïve HCC over an 18-month period, allowing for a minimum of 6 months follow up. Patients will undergo a CEUS examination within two weeks of their first two clinically indicated CT\u002FMRI exams (obtained at Jefferson 1-2 months and 4-6 months post TARE). In patients retreated prior to their 4-6 month MRI, CEUS may also be performed in the absence of the MRI at this time point but prior to retreatment. Patients will be recruited across six major hospitals within the Jefferson Health Enterprise. Those eligible for participation will be identified by project co-investigators and contacted by the study coordinator to discuss participation and to explain the study. The patient will be given time to consider the risks and benefits of the study and ask questions about participation. If agreeable, the patient will then arrange with the project coordinator to come to Jefferson's center city campus to sign consent and take part in the research study.",[482,138,30,745,746,710],"Hepatic Neoplasm","Primary Liver Cancer",[748,739,749,750,751,752,482,753,754,755,756,757,758,759,760,761,762,763,764,765,766,767,768,769,770],"transarterial radioembolization","CEUS","contrast-enhanced ultrasound","hepatocellular","carcinoma","hepatocellular carcinoma (HCC)","liver cancer","liver tumors","liver lesions","microbubbles","liver parenchyma","liver imaging","HCC locoregional therapy","Ultrasound","Kupffer","Yttrium-90","tumor viability","time intensity curves","parametric maps","microbubble destruction","bolus contrast injection","CEUS biomarker","Y90 TARE","2026-06-08",{"date":773,"type":43},"2026-06-10",{"date":775,"type":43},"2025-09-11",{"date":777,"type":22},"2027-06-30",{"name":779,"class":75},"Thomas Jefferson University"]